UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016511
Receipt number R000019175
Scientific Title SpO2 area of the 6 minute-walk test
Date of disclosure of the study information 2015/02/16
Last modified on 2021/02/22 12:26:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

SpO2 area of the 6 minute-walk test

Acronym

SpO2 area of the 6 minute-walk test

Scientific Title

SpO2 area of the 6 minute-walk test

Scientific Title:Acronym

SpO2 area of the 6 minute-walk test

Region

Japan


Condition

Condition

Idiopathic pulmonary fibrosis
Chronic Obstructive Pulmonary Disesase
Combined Pulmonary Fibrosis and Emphysema

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the usefulness of the SpO2 area in patients with IPF/COPD/CPFE.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change in SpO2 area

Key secondary outcomes

1.Change in 6 minute-walk distance.
2.Changes in pulmonary function test(VC, FVC, FEV1, FEV1/FVC, DLco, DLco/VA, R5, R20, R5-R20, X5, Fres, ALX).


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. FVC>1.0L in IPF/CPFE patients
2. 30%<=%FEV1<80% in COPD patients
3. all patients provide written informed consent.

Key exclusion criteria

1. patients who received therapy of the lung cancer.
2. patient who have treatment with the home oxygen therapy.
3. patients who had a history of the angina pectoralis within 1 month.
4. patient who have walking disturbance.
5. considered ineligible for the study by the investigator.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Akito
Middle name
Last name Yamamoto

Organization

Shizuoka General Hospital

Division name

Respiratory medicine

Zip code

420-8527

Address

4-27-,Kita-ando,Aoi-ward,Shizuoka,Shizuoka,Japan

TEL

054-247-6111

Email

akito-yamamoto@i.shizuoka-pho.jp


Public contact

Name of contact person

1st name Akito
Middle name
Last name Yamamoto

Organization

Shizuoka General Hospital

Division name

Respiratory medicine

Zip code

420-8527

Address

4-27-,Kita-ando,Aoi-ward,Shizuoka,Shizuoka,Japan

TEL

054-247-6111

Homepage URL


Email

akito-yamamoto@i.shizuoka-pho.jp


Sponsor or person

Institute

Shizuoka General Hospital

Institute

Department

Personal name



Funding Source

Organization

Shizuoka General Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shizuoka General Hospital

Address

4-27-,Kita-ando,Aoi-ward,Shizuoka,Shizuoka,Japan

Tel

054-247-6111

Email

chiken-sougou@shizuoka-pho.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 16 Day


Related information

URL releasing protocol

https://www.tandfonline.com/doi/full/10.1080/15412555.2020.1844176

Publication of results

Published


Result

URL related to results and publications

https://www.tandfonline.com/doi/full/10.1080/15412555.2020.1844176

Number of participants that the trial has enrolled

57

Results

In multivariate regression analysis, a 6MWD less than 350m was independently predicted by CAT scores and inspiratory R5. In ROC, the AUC was 0.76, 0.78, and 0.85 for CAT scores, R5, and CAT scores plus R5, respectively, with the best cutoff value of 17 and 2.82 cmH20/L/s. In conclusion, inspiratory R5, predicted low exercise tolerance in COPD subjects.

Results date posted

2021 Year 02 Month 22 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

This was a prospective, observational study. Fifty-seven subjects with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between April 2015 and April 2016.

Participant flow

Of the 57 total subjects, 43 (75.4%) had a 6MWD and over 350m, and 14 (24.6%) had a 6MWD less than 350m.

Adverse events

None, as this is an observational study.

Outcome measures

Modified MRC dyspnea scale (mMRC), COPD Assessment Test (CAT), oscillometry, spirometry, and 6MWT were performed in a stable condition. The participants were classified into subjects with 6MWD and over 350m or 6MWD less than 350m, and the predictor of 6MWD less than 350m was assessed.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2015 Year 01 Month 27 Day

Date of IRB

2015 Year 01 Month 27 Day

Anticipated trial start date

2015 Year 02 Month 16 Day

Last follow-up date

2017 Year 11 Month 30 Day

Date of closure to data entry

2017 Year 11 Month 30 Day

Date trial data considered complete

2018 Year 02 Month 01 Day

Date analysis concluded



Other

Other related information

Study design
1. A prospective, obserbational study
2. Method: To compare changes in Pulmnary Function Test,6 minute-walk test. 1-year changes for patients with mild to moderate stable IPF/COPD/CPFE.


Management information

Registered date

2015 Year 02 Month 11 Day

Last modified on

2021 Year 02 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019175


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name